Skip to main content

8 Result(s)

within Chitomi Hasebe Remove this filter

and

  1. No Access

    Article

    Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group

    This study aimed to describe the real-world efficacy and safety of the combination therapy of atezolizumab and bevacizumab (Atezo/Bev) for unresectable hepatocellular carcinoma (HCC). This retrospective analys...

    Shintaro Takaki, Masayuki Kurosaki, Nami Mori, Keiji Tsuji… in Investigational New Drugs (2023)

  2. No Access

    Article

    Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab

    Alpha-fetoprotein (AFP) response (relative decline in AFP) is associated with imaging response evaluated by response evaluation criteria in solid tumors ver1.1 (RECIST) and survival in treatment for hepatocell...

    Nobuharu Tamaki, Toshifumi Tada, Masayuki Kurosaki… in Investigational New Drugs (2022)

  3. Article

    Open Access

    Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score

    Nucleos(t)ide analogs (NA) suppress hepatitis B virus (HBV) replication and reduce the risk of hepatocellular carcinoma (HCC). However, NA cannot suppress carcinogenesis completely in patients with chronic hep...

    Shun Kaneko, Masayuki Kurosaki, Kouji Joko, Hiroyuki Marusawa… in Scientific Reports (2020)

    Download PDF (1794 KB) View Article

  4. No Access

    Article

    Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection

    Until recently, interferon-free anti-hepatitis C virus (HCV) therapy for genotype 2 (GT2) HCV-infected hemodialysis patients was an unfulfilled medical need. Recent clinical trials of glecaprevir and pibrentas...

    Goki Suda, Chitomi Hasebe, Masami Abe, Masayuki Kurosaki… in Journal of Gastroenterology (2019)

  5. No Access

    Article

    Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection

    The prevalence of hepatitis C virus (HCV) infection in hemodialysis patients is high and results in a poor prognosis. Thus, safer and more effective treatment regimens are required. In this prospective multice...

    Goki Suda, Masayuki Kurosaki, Jun Itakura, Namiki Izumi… in Journal of Gastroenterology (2019)

  6. No Access

    Article

    Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group

    We aimed to describe the real-world efficacy and safety of combination therapy with ledipasvir and sofosbuvir (LDV/SOF) for chronic hepatitis C virus (HCV) genotype 1 (GT1) infection.

    Keiji Tsuji, Masayuki Kurosaki, Jun Itakura, Nami Mori… in Journal of Gastroenterology (2018)

  7. No Access

    Article

    Effectiveness of pazopanib for postoperative recurrence of granulocyte colony-stimulating factor-producing primary hepatic angiosarcoma

    A 38-year-old Japanese woman was referred to our hospital with complaints of fever, general fatigue, and upper abdominal discomfort. Computed tomography revealed a massive tumor in the right lobe of the liver,...

    Koji Sawada, Manabu Soma, Shunsuke Nakajima… in International Cancer Conference Journal (2015)

  8. No Access

    Article

    Importance of cytotoxic T lymphocytes in the rejection of transplanted hepatocellular carcinoma

    Fischer rats became resistant to syngeneic hepatocellular carcinoma (FAA-HTC1) cells on repeated sensitization with mitomycin C-treated FAA-HTC1 cells. In contrast, FAA-HTC1 cells injected into the liver kille...

    Hironobu Kohda, Chihiro Sekiya, Yoshihiro Torimoto… in Journal of Gastroenterology (1994)